Phibro Animal Health (PAHC) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Share on StockTwits

Phibro Animal Health (NASDAQ:PAHC) announced its quarterly earnings results on Tuesday. The company reported $0.39 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.03), Briefing.com reports. Phibro Animal Health had a net margin of 7.90% and a return on equity of 39.81%. The firm had revenue of $200.20 million during the quarter, compared to analyst estimates of $203.99 million. During the same period last year, the firm earned $0.38 EPS. Phibro Animal Health’s quarterly revenue was up 3.5% on a year-over-year basis. Phibro Animal Health updated its FY 2019 guidance to $1.68-1.72 EPS and its FY19 guidance to $1.68-1.72 EPS.

Shares of PAHC stock traded down $3.48 on Wednesday, hitting $38.70. The stock had a trading volume of 360,200 shares, compared to its average volume of 112,970. Phibro Animal Health has a twelve month low of $32.05 and a twelve month high of $54.62. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of 22.24, a price-to-earnings-growth ratio of 3.55 and a beta of 0.82. The company has a quick ratio of 1.66, a current ratio of 2.90 and a debt-to-equity ratio of 1.62.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 19th. Stockholders of record on Wednesday, November 28th will be issued a $0.12 dividend. This is a positive change from Phibro Animal Health’s previous quarterly dividend of $0.10. The ex-dividend date of this dividend is Tuesday, November 27th. This represents a $0.48 annualized dividend and a dividend yield of 1.24%. Phibro Animal Health’s payout ratio is 22.99%.

Several equities analysts have recently issued reports on the stock. BidaskClub lowered shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. Zacks Investment Research lowered shares of Phibro Animal Health from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 24th. Finally, Morgan Stanley boosted their price target on shares of Phibro Animal Health from $36.00 to $46.00 and gave the company an “underweight” rating in a report on Wednesday, August 29th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. Phibro Animal Health currently has an average rating of “Hold” and a consensus price target of $43.20.

In related news, CEO Jack Bendheim sold 10,000 shares of the company’s stock in a transaction on Monday, August 13th. The shares were sold at an average price of $50.03, for a total value of $500,300.00. Following the completion of the transaction, the chief executive officer now directly owns 60,000 shares of the company’s stock, valued at approximately $3,001,800. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel M. Bendheim sold 2,500 shares of the company’s stock in a transaction on Wednesday, September 12th. The stock was sold at an average price of $44.30, for a total transaction of $110,750.00. Following the completion of the transaction, the vice president now directly owns 2,500 shares of the company’s stock, valued at $110,750. The disclosure for this sale can be found here. Insiders sold a total of 143,020 shares of company stock valued at $6,967,571 in the last three months. 50.29% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in PAHC. Royal Bank of Canada boosted its stake in Phibro Animal Health by 2,104.6% in the 1st quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock worth $151,000 after purchasing an additional 3,641 shares during the period. Meeder Asset Management Inc. boosted its stake in Phibro Animal Health by 149.2% in the 2nd quarter. Meeder Asset Management Inc. now owns 4,470 shares of the company’s stock worth $206,000 after purchasing an additional 2,676 shares during the period. Piedmont Investment Advisors LLC acquired a new position in Phibro Animal Health in the 2nd quarter worth $213,000. Janus Henderson Group PLC acquired a new position in Phibro Animal Health in the 2nd quarter worth $222,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Phibro Animal Health in the 2nd quarter worth $255,000. 47.95% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://weekherald.com/2018/11/07/phibro-animal-health-pahc-posts-quarterly-earnings-results-misses-estimates-by-0-03-eps.html.

About Phibro Animal Health

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.

Featured Article: How to Invest in the Dividend Aristocrat Index

Earnings History for Phibro Animal Health (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply